ETHICAL ASPECTS OF THE COOPERATION BETWEEN PHYSICIAN AND PHARMACEUTICAL INDUSTRY
Abstract
Background. It is not possible to isolated ethical aspects and norms in the work of physician from the professional and scientific ones. The physician will not act contrary to ethical principles if he will work for the interests of the patient and in accordance with scientific knowledge.
Present situation and possible solutions. Every physician, especially if working in university institution is co-operating with pharmaceutical industry, at least he is makes the prescriptions and chooses one drug of the possible ones. There are also other aspects of co-operation: clinical trials, writing expertise and lectures at scientific meetings, sponsored by pharmaceutical industry. There are guidelines and codex in Western countries for more than ten years, which regulate the relation between physician and pharmaceutical industry. The most important ones are those from World Health Organisation, European Federation of Pharmaceutical Industries’ Associations’, and International Federation of Pharmaceutical Manufacturers Associations’. Scientific independence of lecturers and writers is tried to be achieved by disclosure of relevant financial relation with pharmaceutical corporation in advance.
Conclusions. Physician working with pharmaceutical industry has o follow the guidelines of international professional associations. He/she has to be independent relaying only upon scientific and professional principles seeing primary the benefit of the patient.
Downloads
References
2. Goldfinger SE. Physicians and the pharmaceutical industry. Ann Intern Med 1990; 112: 624–6.
3. Weber W. Sponsored continuing medical education under scrutiny in Europe. Lancet 2001; 357: 452–2.
4. Yamey G. Pen »amnesty« for doctors who shun drug companies. BMJ 2001; 322: 69–9.
5. Sheldon T. GPs warned on accepting hospitality from drug companies. BMJ 2001; 322: 194–4.
6. Dyer C. English GP suspended for misleading drug companies. BMJ 2000; 321: 1366–6.
7. Sheldon T. Drug company fined for exessive hospitality. BMJ 2001; 322: 382–2.
8. Smith GD, Ebrahim S, Frankel S. How policy informs the evidence. BMJ 2001; 322: 184–5.
9. Del Mar CB, Glasziou PP. Ways of using evidence-based medicine in general practice. Med J Australia 2001; 174: 347–50.
10. Craig JC, Stockler MR. Evidence-based medicine: useful tools for decision making. Med J Australia 2001; 174: 248–53.
11. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: Attitudes and practices of medicine hausstaff toward pharmaceutical industry promotion. Am J Med 2001; 110: 551–7.
12. Morris LA, Pines WL. Regulation of pharmaceutical promotion in the twenty-first century. Drug Information Journal 2000; 34: 861–73.
13. Zakon o zdravilih in medicinskih pripomočkih. Uradni list RS 1999. http:// www2.gov.si
14. WHO: WHO ethical criteria for medicinal drug promotion. Geneva: WHO, 1994: 1–16.
15. Council of the European Communities. Council directive 92/28/EEC of 31 March 1992 on the advertising of medical products for human use. Brussels: The Council of the European Communities, 1992: 115–23.
16. Association of the British Pharmaceutical Industry. Code of practice for the pharmaceutical industry. London: The Association of the British Pharmaceutical Industry, 1998: 1–44.
17. World Medical Association. Revised comments on the proposed WMA statement on the clinical independence and professional integrity of the physician. Divonne-les-Bains: WMA, 2001: 1–13.
18. Council on Ethical and Judicial Affairs of the American Medical Association. Guidelines on gifts to physicians from industry: An update. Food and Drug Law Journal 2001; 56: 27–40.
19. Canadian Medical Association. Physicians and the pharmaceutical industry. Can Med Assoc J 1994; 150: 256A–256C.
20. Association of American Medical Colleges. Guidelines for faculty involvement in commercially supported continuing medical education. Academic Medicine 1992; 67: 615–21.
21. Slovensko farmacevtsko društvo. Kodeks farmacevtske etike SFD. Farm Vestn 2000; 51: 324–5.
22. Gervais L. Policy on conflict of financial interest. Ottawa: Royal College of Physicians & Surgeons of Canada, 1996: 1–2.
23. Lo B, Wolf LE, Berkeley A. Conflict-of-interest polices for investigators in clinical trials. N Engl J Med 2000; 343: 1616–26.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
